Literature DB >> 17673129

Radioiodine in the treatment of thyroid cancer.

Douglas Van Nostrand1, Leonard Wartofsky.   

Abstract

This article presents an overview of the use of radioactive iodine (131-I) in the treatment of patients who have well differentiated thyroid cancer. We review definitions; staging; the two-principal methods for selection of a dosage of 131-I for ablation and treatment; the objectives of ablation and treatment; the indications for ablation and treatment; the recommendations for the use of 131-I for ablation and treatment contained in the Guidelines of the American Thyroid Association, the European Consensus, the Society of Nuclear Medicine, and the European Association of Nuclear Medicine; the dosage recommendations and selection of dosage for 131-I by the these organizations; and the Washington Hospital Center approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17673129     DOI: 10.1016/j.ecl.2007.04.006

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  17 in total

1.  Mass in the neck after radiation exposure from Chernobyl disaster.

Authors:  John C O'Brien; S Michelle Shiller; Matthew G Cusick; Baron L Hamman
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-04

Review 2.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

3.  Current concepts and future directions in differentiated thyroid cancer.

Authors:  Donald S A McLeod
Journal:  Clin Biochem Rev       Date:  2010-02

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Effects of recombinant human thyroid stimulating hormone on 131I therapy for the treatment of differentiated thyroid cancer.

Authors:  Yiling Guo; Yingnan Zhang; Zuowei Chen; Zhenfu Xin
Journal:  Exp Ther Med       Date:  2015-03-03       Impact factor: 2.447

6.  Image-guided tumor-selective radioiodine therapy of liver cancer after systemic nonviral delivery of the sodium iodide symporter gene.

Authors:  Kathrin Klutz; Michael J Willhauck; Christian Dohmen; Nathalie Wunderlich; Kerstin Knoop; Christian Zach; Reingard Senekowitsch-Schmidtke; Franz-Josef Gildehaus; Sibylle Ziegler; Sebastian Fürst; Burkhard Göke; Ernst Wagner; Manfred Ogris; Christine Spitzweg
Journal:  Hum Gene Ther       Date:  2011-10-11       Impact factor: 5.695

7.  ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.

Authors:  Sandra J Rosenbaum-Krumme; Rainer Görges; Andreas Bockisch; Ina Binse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-06-21       Impact factor: 9.236

8.  A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

9.  Remnant uptake as a postoperative oncologic quality indicator.

Authors:  David F Schneider; Kristin A Ojomo; Herbert Chen; Rebecca S Sippel
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

10.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.